Glenmark launched the drug Favipiravir for the treatment of mild to moderate COVID-19 cases.
They launched it after the Drugs Controller General of India (DCGI) gave permission.
Patients with conditions such as diabetes with mild to moderate COVID-19 symptoms
can take the medicine. Even heart patients infected with COVID can use it.
 The medicines provide relief from the symptoms in four days.
You may think that you can easily buy it.
It will only be given if the patient has a prescription from a doctor.
Only two strips will be allowed per patient.
The medicine has been launched under the brand name FabiFlu.
It will be available as a 200 mg tablet at an MRP of ₹3,500 for a strip of 34 tablets.
The tablets are being produced by the company at its Baddi facility in Himachal Pradesh.
 Glenmark said the drug will be available both through hospitals and medical shops.
FabiFlu is the first approved medication in India for the treatment of COVID-19.
At Delhi's Fortis Hospital, Shalimar Bagh,
 Dr Vikas Maurya, Director, Department of Pulmonology and Sleep Disorders said,
"This drug was already being used in Japan for treatment of Flu.
Even China was using it and Russia had also given permission in May to use it.
Remdesivir and Favipiravir does not cure COVID-19 but provide relief from the Flu.
Experts have found that there was some benefit of Favipiravir
that is why it has now been launched in India.
However people must not think of it as a Magic Drug that will cure COVID-19.
It is only meant to provide relief.
Once they began administering the drug, we will know about its efficacy.
